| Emily Deann Souter, MA, CCC-SLP | |
|
11661 Granada St, Leawood, KS 66211-1473 | |
| (913) 906-0200 | |
| Not Available |
| Full Name | Emily Deann Souter |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 11661 Granada St, Leawood, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386291706 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 4308 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Emily Deann Souter, MA, CCC-SLP 1612 Willow Cv, Lawrence, KS 66046-5093 Ph: (785) 477-5312 | Emily Deann Souter, MA, CCC-SLP 11661 Granada St, Leawood, KS 66211-1473 Ph: (913) 906-0200 |
News Archive
The U.S. Food and Drug Administration today approved Clinolipid (lipid injectable emulsion, USP) for intravenous feeding (parenteral nutrition) in adult patients, providing a source of calories and essential fatty acids for adult patients who are unable to eat or drink. Clinolipid was granted a priority review to help alleviate a drug shortage.
This achievement, which occurred in laboratory mice and is described in the March 1, 2005 issue of the Journal of Cell Science, holds great promise for victims of diseases that destroy the optic nerve, and for sufferers of central nervous system injuries.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
Researchers have found that apoptosis, a natural process of programmed cell death, can reactivate latent herpesviruses in the dying cell. The results of their research, which could have broad clinical significance since many cancer chemotherapies cause apoptosis, was published ahead of print in the Journal of Virology.
Klaumwell Research Labs, LLC, U.S., a subsidiary of Italian multinational Medestea Internazionale, announced positive results from a double-blind, placebo-controlled clinical study published in the prestigious, peer-reviewed International Journal of Obesity which demonstrates the efficacy of key ingredients contained in a new appetite control spray. Fullfast™ is a clinically tested dietary supplement that helps reduce excessive feelings of hunger.
› Verified 9 days ago
Ms. Laura Marie Frye, MA SPED MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7000 W 121st St Ste 110, Leawood, KS 66209 Phone: 913-912-2174 | |
Mrs. Victoria Ann Turner, M.CD, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3715 W 133rd St, Leawood, KS 66209 Phone: 913-948-4223 | |
Margaret Massey, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 4801 College Blvd Ste 100-200, Leawood, KS 66211 Phone: 913-728-0386 | |
Kaitlyn Elizabeth Adam, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3715 W 133rd St, Leawood, KS 66209 Phone: 913-213-3531 | |
Brettell Nicole Lynch, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5420 W 151st St, Leawood, KS 66224 Phone: 913-219-5696 | |
Maha Bishr, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3219 W 82nd Ter, Leawood, KS 66206 Phone: 785-979-4700 | |
Mrs. Erica Leigh Browne, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7000 W 121st St Ste 110, Leawood, KS 66209 Phone: 913-515-9833 |